MAYO CLINIC
Mayo Medical Laboratories

LABORATORY SERVICE REPORT

1-800-533-1710

PATIENT NAME	PATIENT NUMBER	AGE	SEX	ACCESSION #
WARFP, TESTING	L3MRNG9155353	57	F	G9155353

ORDERING PHYSICIAN	CLIENT ORDER #	ACCOUNT #
		LIAISONS

COLLECTION DATE TIME	RECEIVED DATE TIME	REPORT PRINTED DATE TIME	SPECIMEN INFORMATION
08/24/10 04:09 P	08/24/10 04:09 P	08/30/10 12:08 P	DATE OF BIRTH:

Test Client
Attn: Mayo Liaisons
200 First Street SW
Rochester, MN 55905
507-284-8202

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
Rapid DNA Extraction			
Comment	Genomic DNA was extracted.		MCR
Warfarin Sensitivity Genotyping			
Sequencing	Performed		MCR
Warfarin Sensitivity, Genotype			
Warfarin Sens			MCR
Phenotype Interp			

Predicted intermediate warfarin sensitivity
This patient has a genotype associated with intermediate warfarin sensitivity. A moderate dose decrease may be required to maintain optimal INR.
There is a small residual risk of having a rare, undetected polymorphism which may result in high warfarin sensitivity. This should be considered if the predicted phenotype is discordant with clinical findings. See below for a link to the FDA for dosing information.

CYP2C9 Star Alleles/VKORC1 Genotype	1/2 G/A		MCR

Initial drug dosing recommendations for this CYP2C9/VKORC1 genotype is available in Table 5 of the drug label, located online at:
http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/009218s108lbl.pdf
Numerous drugs have been reported to alter the warfarin dosing requirements for patients. The warfarin drug labeling also contains information regarding numerous potential drug interactions and endogenous factors that may impact dosing.

** Perform Site Legend on last page of report*

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
WARFP, TESTING	Final	08/24/10 04:09 P

PATIENT NAME	PATIENT NUMBER	AGE	SEX	ACCESSION #
WARFP, TESTING	L3MRNG9155353	57	F	G9155353

ORDERING PHYSICIAN	CLIENT ORDER #	ACCOUNT #
		LIAISONS

COLLECTION DATE TIME	RECEIVED DATE TIME	REPORT PRINTED DATE TIME	SPECIMEN INFORMATION
08/24/10 04:09 P		08/30/10 12:08 P	DATE OF BIRTH:

Test Client
Attn: Mayo Liaisons
200 First Street SW
Rochester, MN 55905
507-284-8202

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *
For a full description of CYP2C9 alleles, see: http://www.cypalleles.ki.se/cyp2c9.htm			
CYP2C9 430C>T(*2)	C/T		MCR
CYP2C9 818delA(*6)	A/A		MCR
CYP2C9 1075A>C(*3)	A/A		MCR
CYP2C9 1076T>C(*4)	T/T		MCR
CYP2C9 1080C>G(*5)	C/C		MCR
VKORC1 -1639G>A	G/A		MCR
Warfarin Sens			MCR
Genotype Interp			

This patient has one copy of an allele encoding CYP2C9 protein with reduced activity and one copy with normal activity. The patient also has one copy of VKORC1 with normal activity and one with reduced expression. Additional descriptions of the effects of the star alleles and variations on CYP2C9 and VKORC1 function are found in the Mayo Test Catalog (http://www.mayomedicallaboratories.com/test-catalog/).

Warfarin Sensitivity Reviewed by	Dennis J. O'Kane, Ph.D.		MCR

This test was developed and its performance characteristics determined by Laboratory Medicine and Pathology, Mayo Clinic, Rochester MN. It has not been cleared or approved by the U.S. Food and Drug Administration.
Cytochrome P450 2C9 (CYP2C9) metabolizes warfarin and Vitamin K Epoxide Reductase Complex, subunit 1 (VKORC1) is the target of warfarin therapy. The combined genotype can be used to predict an individual's response to warfarin therapy. Bidirectional DNA sequence analysis was used to test for the presence of variants in exons 3, 5, and 7 of the CYP2C9 gene as well as in VKORC1's distal promoter. These sequencing reactions detect the presence of CYP2C9

** Perform Site Legend on last page of report*

PATIENT NAME	PATIENT NUMBER	AGE	SEX	ACCESSION #
WARFP, TESTING	L3MRNG9155353	57	F	G9155353

ORDERING PHYSICIAN	CLIENT ORDER #	ACCOUNT #
		LIAISONS

COLLECTION DATE TIME	RECEIVED DATE TIME	REPORT PRINTED DATE TIME	SPECIMEN INFORMATION
08/24/10 04:09 P		08/30/10 12:08 P	DATE OF BIRTH:

Test Client
Attn: Mayo Liaisons
200 First Street SW
Rochester, MN 55905
507-284-8202

TEST REQUESTED	HI LO	REF RANGE	PERFORM SITE *

430C>T (*2), 818delA (*6), 1075A>C (*3), 1076T>C (*4), 1080C>G (*5), and VKORC1 -1639G>A. This sequencing assay will not detect all the known mutations that result in decreased or inactive CYP2C9 or VKORC1. Rare polymorphisms could interfere with test results. Absence of a detectable gene mutation or polymorphism does not rule out the possibility that a patient has an intermediate or high sensitivity phenotype due to the presence of an undetected polymorphism or due to drug-drug interactions.

* PERFORMING SITE

MCR	Mayo Clinic Dpt of Lab Med & Pathology 200 First Street SW Rochester, MN 55905	Lab Director: Franklin R. Cockerill, III, M.D.

PATIENT NAME	ORDER STATUS	COLLECTION DATE AND TIME
WARFP, TESTING	Final	08/24/10 04:09 P